ADSTILADRIN

This brand name is authorized in United States.

Active ingredients

The drug ADSTILADRIN contains one active pharmaceutical ingredient (API):

1
UNII 0OOS09O1FH - NADOFARAGENE FIRADENOVEC
 

Nadofaragene firadenovec is a non-replicating recombinant type 5 adenovirus vector-based gene therapy containing the human IFNα2b transgene. Intravesical administration of nadofaragene firadenovec results in the entry of viral particles into the tumour cells and the urothelium that make up the luminal surface of the bladder, leading to the expression of IFNα2b protein by those cells. In the transduced cells, the viral DNA does not integrate into the genome. Treatment with nadofaragene firadenovec has shown anti-tumour effects in mice with bladder (cancer cell) xenografts.
 
Read more about Nadofaragene firadenovec

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 ADSTILADRIN Intravesical suspension MPI, EU: SmPC European Medicines Agency (EU)
 ADSTILADRIN Suspension for intravesical instillation MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
L01XL10 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
US FDA, National Drug Code 55566-1050

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈